title: Quality of life improvement in Latin American patients suffering from chronic venous disorder using a combination of Ruscus aculeatus and hesperidin methyl-chalcone and ascorbic acid (quality study).
abstract: OBJECTIVE
  The present study assessed the effect of Ruscus aculeatus, hesperidin methyl-chalcone and ascorbic acid (HMC-AA), in the treatment of chronic venous disorders (CVD) in Latin American patients.
  
  
  METHODS
  This study is an observational, single arm, multicentric and prospective trial. Patients suffering from CVD and belonging to C0s-C3 Clinical Etiological Anatomical and Physiopathological (CEAP) classes were included. Patient profiles, risk factors, clinical symptomatology and quality of life (QoL) assessed by SF-12 and CIVIQ questionnaires were evaluated at inclusion and after 12-week treatment.
  
  
  RESULTS
  The main factors influencing the previous management of patients were age, gender, body mass index (BMI), familial history, physical activity, exposure to heat, heavy loads lifting, profession and clinical characteristics. All clinical symptoms significantly improved with treatment and, as BMI and CEAP classes increased. Ankle circumferences decreased over time, correlating with BMI and CEAP classes. The physical and psychological dimensions of the SF-12 score significantly increased over time and improved within each CEAP class. The CIVIQ score significantly improved over time, correlating with age and CEAP classes.
  
  
  CONCLUSIONS
  A 12-week treatment with Ruscus aculeatus HMC-AA showed a significant decrease in the clinical symptoms and a significant improvement in the QoL of patients with CVD.
authors.affiliation: Cabinet de Phlébologie, 32 Boulevard Dubouchage, Nice, France. jj.guex@wanadoo.fr
authors.forename: J J
authors.initials: JJ
authors.lastname: Guex
authors.forename: L
authors.initials: L
authors.lastname: Avril
authors.forename: E
authors.initials: E
authors.lastname: Enrici
authors.forename: E
authors.initials: E
authors.lastname: Enriquez
authors.forename: C
authors.initials: C
authors.lastname: Lis
authors.forename: C
authors.initials: C
authors.lastname: Taïeb
mesh_terms: D000328:Adult; D000368:Aged; D001118:Argentina; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D047188:Chalcones / Q000627:therapeutic use*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006569:Hesperidin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D008800:Mexico; D008875:Middle Aged; D016017:Odds Ratio; D028321:Plant Preparations / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D031443:Ruscus; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology
chemical_list: D002317:Cardiovascular Agents; D047188:Chalcones; D004338:Drug Combinations; D028321:Plant Preparations; C033022:hesperidin methylchalcone; D006569:Hesperidin; D001205:Ascorbic Acid